Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

First Derivatives CEO Will Remain With Company During Cancer Treatment

17th May 2019 08:49

LONDON (Alliance News) - First Derivatives PLC on Friday said Chief Executive Officer Brian Conlon has recently been diagnosed with cancer and will remain as CEO during his treatment.

The trading software developer said Conlon will receive ongoing weekly treatment which will include chemotherapy. The treatment is likely to last for a number of months.

First Derivatives Chair Seamus Keating said: "The board has set a clear strategy and the executive committee, led by Brian, has delivered strong execution of that strategy year-on-year. During the period of his treatment I will provide additional executive and governance support and I am confident that Brian and his team will continue to execute the group's growth plans successfully."

Shares in First Derivatives were down 1.1% at 3,065.00 pence on Friday morning.


Related Shares:

FD Technologies
FTSE 100 Latest
Value8,809.74
Change53.53